Abstract
Venetoclax+rituximab (VEN+RTX) is a potent anti-leukemic therapy for relapsed/refractory chronic lymphocytic leukemia (R/R CLL), superior to bendamustine+rituximab (BEND+RTX) based on the results of the MURANO trial. However, the relative efficacy and safety of VEN+RTX compared to other treatment options remain unknown. This study aimed to compare VEN+RTX with other possible therapies for R/R CLL, including BTK and PI3K inhibitors, chemotherapy, and/or immunotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
